Noxopharm’s SOF-16 Shows Strong Anti-Inflammatory Effects in Lupus and Arthritis Samples

SOF-16 Demonstrates Potent Anti-Inflammatory Activity in Patient Samples

Noxopharm Limited (ASX:NOX) has released compelling preclinical data showing its lead Sofra™ platform compound, SOF-16, effectively suppresses inflammatory responses in blood and joint fluid samples from patients with systemic lupus erythematosus (SLE) and rheumatoid arthritis. This marks the first time SOF-16, the active ingredient in the company’s SOF-SKN topical drug candidate, has been tested ex vivo on autoimmune disease patient material.

The findings, detailed in a bioRxiv preprint by Professor Michael Gantier from the Hudson Institute of Medical Research and collaborators including Noxopharm staff and partners Tezcat Biosciences and InhaTarget Therapeutics, reveal SOF-16’s ability to block Toll-like receptor 7 (TLR7)-mediated inflammation, a key driver of autoimmune pathology. Blood samples from SLE patients with a genetic mutation causing TLR7 hypersensitivity showed elevated inflammatory markers when stimulated in vitro, which SOF-16 treatment reduced by over 90%.

Similarly, synovial fluid from rheumatoid arthritis patients induced a robust inflammatory response in TLR7-responsive cells that was nearly eliminated with SOF-16. These results bolster the rationale for expanding SOF-16’s development beyond cutaneous lupus erythematosus (CLE) into systemic autoimmune indications, a move that could significantly broaden the drug’s market potential.

Translating Breakthrough Research into Therapeutic Candidates

The new data builds on a high-profile Nature Immunology paper by Professor Gantier that has attracted significant academic attention, with the preprint providing early access to additional translational research. Noxopharm CEO Dr Olivier Laczka emphasised the momentum generated by these studies, noting the Sofra platform’s versatility in addressing a range of autoimmune and inflammatory diseases beyond topical skin conditions.

SOF-SKN, the topical formulation of SOF-16, is initially targeting the US$3.3 billion global CLE market, with plans to explore applications in psoriasis, dermatomyositis, rheumatoid arthritis, and diabetes. These indications share underlying immune dysregulation mechanisms that Sofra’s oligonucleotide-based technology aims to modulate.

Importantly, the Sofra platform’s oligonucleotide approach can both reduce and stimulate immune responses, offering a novel mechanism to control disease at its source. This complements recent advancements in delivery methods, including inhalable lipid nanoparticles developed in partnership with InhaTarget Therapeutics, which recently demonstrated significant lung inflammation reduction in preclinical models, highlighting Sofra’s expanding therapeutic reach and delivery versatility.

Positioning for Regulatory Submissions and Clinical Development

While the data remains preclinical and in vitro, it adds weight to Noxopharm’s growing evidence base as it prepares for future regulatory filings. The company’s strategic collaborations and leadership changes, including the appointment of Dr Olivier Laczka as CEO, are aligned to accelerate Sofra platform progress and clinical trial initiations.

Investors will note that the preprint has not undergone peer review, and clinical efficacy and safety remain to be demonstrated in human trials. However, the clear anti-inflammatory effects in patient-derived samples provide a promising signal that SOF-16 could address unmet needs in autoimmune disease treatment.